world cancer report - iarc
world cancer report - iarc
world cancer report - iarc
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Vaccine Site of trial Number of patients Condition of patients<br />
Recombinant vaccinia UK (University of Wales) 8 Advanced cervical <strong>cancer</strong><br />
HPV 16 and18 E6 and E7 proteins UK (University of Wales) 10 CIN III lesions<br />
(Cantab Pharmaceuticals, UK) US (NCI) 14 Advanced cervical <strong>cancer</strong><br />
UK, The Netherlands, Belgium, 18 Early invasive cervical <strong>cancer</strong><br />
Germany and Sweden<br />
HPV 6-L2 E7 fusion protein UK (London) 36 Genital warts<br />
(Cantab Pharmaceuticals, UK)<br />
HPV 16-E7 protein Australia (Queensland) 5 Advanced cervical <strong>cancer</strong><br />
HPV 16-E7 peptide The Netherlands 15 Advanced cervical <strong>cancer</strong><br />
(Leiden University)<br />
HPV 16-peptide US (Norris Cancer Center, USC) 45 CIN II-III lesions<br />
15 VIN lesions<br />
HPV 16-E7 peptide US (NCI) 15 Recurrent or refractory cervical<br />
(Cytel Co, US) <strong>cancer</strong><br />
Table 4.11 Phase I-II clinical trials with HPV therapeutic vaccines.<br />
grammes should help to reduce the period<br />
between availability of an appropriate HPV<br />
vaccine and its introduction for routine<br />
REFERENCES<br />
1. IARC (1995) Human Papillomaviruses (IARC<br />
Monographs on the Evaluation of Carcinogenic Risks to<br />
Humans, Vol. 64), Lyon, IARCPress.<br />
2. Kirnbauer R, Chandrachud L M, O'Neil B W, Wagner E<br />
R, Grindlay G J, Armstrong A, McGarvie G M, Schiller J T,<br />
Lowy D R, Campo M S (1996) Virus-like particles of bovine<br />
papillomavirus type 4 in prophylactic and therapeutic<br />
immunization. Virology, 219: 37-44.<br />
3. Suzich J A, Ghi S J, Palmer-Hill F (1995) Systemic immunization<br />
with papillomavirus L1 protein completely prevents<br />
the development of viral mucosal papillomavirus. Proc Natl<br />
Acad Sci, 92: 11553-11557.<br />
4. Jansen K U, Rosolowsky M, Schultz L D, Markus H Z,<br />
Cook J C, Donnelly J J, Martinez D, Ellis R W, Shaw A R<br />
(1995) Vaccination with yeast-expressed cottontail rabbit<br />
papillomavirus (CRPV) virus-like particles protects rabbits<br />
from CRPV-induced papilloma formation. Vaccine, 13:<br />
1509-1514.<br />
5. Schiller J T, Roden R B (1995) Papillomavirus-like particles.<br />
Papillomavirus Rep, 6: 121-128.<br />
6. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z,<br />
Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA,<br />
Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity<br />
trial in adult volunteers of a human papillomavirus<br />
150 Prevention and screening<br />
use. However, it is unlikely that this will<br />
happen within the next 15-20 years.<br />
Meanwhile efforts should continue to<br />
16 L1 virus-like particle vaccine. J Natl Cancer Inst, 93:<br />
284-292.<br />
7. Bosch F X, Manos M M, Muñoz N, Sherman M, Jansen<br />
A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K<br />
V (1995) Prevalence of human papillomavirus in cervical<br />
<strong>cancer</strong>: a <strong>world</strong>wide perspective. International biological<br />
study on cervical <strong>cancer</strong> (IBSCC) Study Group. J Natl<br />
Cancer Inst, 87: 796-802.<br />
8. Coursaget P, Muñoz N (1999) Vaccination against<br />
infectious agents associated with human <strong>cancer</strong>. In:<br />
Newton R, Beral V, Weiss RA eds, Infection and Human<br />
Cancer, Vol. 33, New York, Cold Spring Harbor Laboratory<br />
Press, 355-381.<br />
8. McNeil C (1997) HPV vaccine treatment trials proliferate,<br />
diversify. J Natl Cancer Inst, 89: 280-281.<br />
10. Borysiewicz L K, Fiander A, Nimako M, Man S,<br />
Wilkinson G W, Westmoreland D, Evans A S, Adams M,<br />
Stacey S N, Boursnell M E, Rutherford E, Hickling J K, Inglis<br />
S C (1996) A recombinant vaccinia virus encoding human<br />
papillomavirus types 16 and 18, E6 and E7 proteins as<br />
immunotherapy for cervical <strong>cancer</strong>. Lancet, 347: 1523-<br />
1527.<br />
introduce or improve existing screening<br />
programmes for cervical <strong>cancer</strong><br />
(Screening for cervical <strong>cancer</strong>, p167).<br />
WEBSITE<br />
Vaccines, Immunization and Biologicals (WHO):<br />
http://www.who.int/vaccines/en/hpvrd.shtml